ANDA 89219, held by ANI Pharmaceuticals. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89219 (Procainamide Hydrochloride), held by ANI Pharmaceuticals, was first approved by FDA on Jul 1, 1986, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 1986 | Original application | Approved | None posted |
| Procainamide Hydrochloride250MG · capsule;oral | Procainamide Hydrochloride | Discontinued |
| Procainamide Hydrochloride375MG · capsule;oral | Procainamide Hydrochloride | Discontinued |
| Procainamide Hydrochloride500MG · capsule;oral | Procainamide Hydrochloride | Discontinued |
| Jan 24, 1994 | Supplement 6Manufacturing | Approved | None posted |
| Feb 14, 1991 | Supplement 5Labeling | Approved | None posted |
| Oct 20, 1988 | Supplement 4Labeling | Approved | None posted |
| Jul 14, 1987 | Supplement 1Manufacturing | Approved | None posted |
| Jul 14, 1987 | Supplement 2Manufacturing | Approved | None posted |
| Jul 14, 1987 | Supplement 3Manufacturing | Approved | None posted |
| Jul 1, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters